@article {2388, title = {The Effect of HBOT on SIRT-1 and SYNDECAN-1 as Therapeutic Targets for Endothelial Dysfunction}, journal = {Pharmacognosy Journal}, volume = {16}, year = {2024}, month = {October 2024}, pages = {1090-1095}, type = {Research Article}, chapter = {1090}, abstract = {

Background: The effect of HBO2 alone on Sirt-1 and Syndecan-1 is unknown, even though both molecules are involved in preventing endothelial dysfunction. This study aims to determine the effect of HBO2 on Sirt-1 and Syndecan-1 as therapeutic targets for endothelial dysfunction. Method: This study employed a true experimental post-test design. Twenty male Sprague Dawley rats aged 12-14 weeks were divided into two groups. Diving was carried out in an animal hyperbaric chamber with a dose of 2.4 ATA for 60 minutes. All data were collected 18 hours after diving. Results: Our study revealed that the administration of HBO caused an increase in serum MDA and endothelial NF-kB levels (p = 0.007; p = 0.001, respectively) without an increase in any inflammatory markers, specifically IL-1 and VCAM-1 levels (p = 0.707; p = 0.168, respectively). HBO2 decreased Syndecan-1, a marker of endothelial injury (p = 0.026), but did not affect endothelial eNOS and Sirt-1. Conclusion: HBO2 did not cause endothelial injury and inflammation, but the dose used was not enough to increase Sirt-1 levels. Additional research is needed to determine a hormesis dose that can increase Sirt-1 levels.

}, keywords = {Endothelial dysfunction, HBO2, Sirt-1, Syndecan-1}, doi = {10.5530/pj.2024.16.177}, author = {Sofia Wardhani and Aryati Aryati and Bambang Purwanto} }